CCHT(SZ:000661) Ge Long Hui·2026-01-23 08:00Core Viewpoint - Changchun High-tech (000661.SZ) announced that its subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd. (referred to as "Jinsai Pharmaceutical"), has received approval from the National Medical Products Administration for the clinical trial application of its drug GenSci145 tablets, which is a novel selective PI3Kα inhibitor intended for the treatment of locally advanced or metastatic solid tumors with PIK3CA mutations [1]. Group 1 - Jinsai Pharmaceutical's GenSci145 tablets are classified as a Class 1 innovative chemical drug [1]. - The drug is specifically designed for patients carrying PIK3CA mutations [1]. - The approval marks a significant milestone in the development of targeted therapies for specific cancer mutations [1].